as of the last version of complaint i saw thomas is asking

New Post Public Reply Private Reply Replies (2) Message Board
microcaps
657
as of the last version of complaint i saw thomas is asking NNLX to recreate financials back to 2014?
if NNLX could not afford to present financials in otc format back then they certainly cannot afford to hire a specialized forensic accountant to recreate them now

he wants a shareholders meeting so he can take control of NNLX at such meeting

he bought stock after the damage was already done so perhaps in the range of .001 to .00001 - you can accumulate a lot of stock at that price very cheaply
you dont have to have a majority of the stock to win shareholder meetings.
if nobody else has a larger block of stock you can win on as low as perhaps 1/3 of the stock
does Bret have a poison pill- a construction to keep a hold of the company in case of a hostile take over- I dont remember our previous discussion on that
he listed probably anywhere from 70 - 99 items.

he wants the court case if he can get standing in New Jersey where he reportedly lives.
a lot of companies choose to register in corporate friendly states for various reasons
Such registration usually has very limited value in determining jurisdiction.
Jurisdiction usually is where the corporation is actually physically located-which was Hubbard Ohio
In violation of the general rules of jurisdiction he wants case in NJ

He is not the first to argue that fax machines etc make it unnecessary to follow general rules. In all cases I've been aware of the judge has denied such arguments.

He wants a direct action instead of a stockholder class action bc a direct action doesn't just put him at the head of the class it puts him above the class - he wants to become as noted the new chairman w apparent ownership of 60% of the stock -a greater % than ceo Bret

he wants the patents to be decisively ruled as property of NNLX which he is trying to take over
in 2004 there was a lawsuit between the previous company - before Bret et al -part of the problem there was the valuation of the patents

its hard to value patents beyond a cost basis
if thomas has some kind of private agreement w some medical company to use one or more of the many patents that would increase the value of said patents
thomas hasnt revealed any such for he wants to get NNLX as cheaply as possible

thomas wants standing. he has admitted to buying the stock after all the damage from NNLX's violations occurred
so he wants to be made whole for things he knew going in-and not just that- he wants to be elected Ceo and chairman etc w 60% of the stock

and that is just what can be determined at the present time

is this a one time thing? hedge funds patrol low pennies to short them into oblivion,violating normal rules of shorting
real estate investors take advantage of homeowners financial troubles offering generally anywhere from 10 to 70 cents on the dollar
since covid those who deal regularly w scams say scams have multiplied astronomically

many here will now say NNLX was a scam. It wasnt - there are a lot of easier ways to scam than painfully nurse such a company reportedly without salary or compensation from stock. Most if not all officers and directors reportedly having other paying jobs except for maybe ceo bret.

just presenting facts- so keep your eyes open, though its apparent some are not
Over 90% of low penny startups fail. Many such low penny startups violate different forms of fiduciary duty. That does NOT make it right but how can so many usually blame the company as if the company was personally out to get them

the biggest violation was not getting back to us after the big PR re 3 major things Brets superlawyer brother (apparently has 2 other lawyer brothers bart and daniel) and NNLX were going to do to get current with otc etc

Does somebody have easy access to that PR who can post it so we can be reminded?

You know when thomas actually files the complaint NNLX will probably have 20 days to put in an appearance.
the judge's first decison is probably, does thomas have standing as part a direct - not class action shareholder- suit.

or actually could first deny the attempt to give new jersey jurisdiction
in which case thomas would probably file in ohio- where the normal obvious jurisdiction would be

those are the first points NNLX would argue in their response

only after standing and venue are determined would any discovery-interrogatories and depositions- begin-which can take a long time.

that situation makes it harder for thomas to get standing whereas a class action stockholder suit would have much easier time achieving standing for many many stockholders have had material losses
1

Nanologix Inc (NNLX) Stock Research Links

NNLX Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Evotec’s $2.9M Grant Advances Drug Safety Tech

Updated Category News Views 87

Revitalizing Drug Development with Human Stem Cells Evotec's latest win—a crisp $2.9 million grant from the Gates Foundation—is like a shot of adrenaline for drug safety innovation. This isn't just another drop in the bucket; it's a solid boost toward improving how we screen potential drugs for fetal risks before they're tossed into the costly whirlpool of clinical...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 399

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 448

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
Segway Powersports Dominates Baja 1000 with Class 2 Sweep

Updated Category News Views 72

Catching the eye of any betting man, Segway Powersports has turned its maiden outing at the relentless SCORE Baja 1000 into a rousing victory. Their arrival on this unforgiving stage with a one-two in Class 2 isn't just a lucky roll—you don't chance upon podium sweeps in such gritty contests. Dissecting the Drive: Commitment and Coordination Unfolding across Baja's...

Continue Reading
Pollo AI Unveils York AI: Automating Social Growth

Updated Category News Views 0

York AI Debuts as the New Kid on the Block Amid the hustle and bustle of a tech-savvy Singapore, Pollo AI’s latest offering, York AI, sashays onto the scene with the promise of putting social media growth on cruise control. We're talking about a digital sidekick that seems to know your online persona better than you do. It’s tailored for everyone from the small-time...

Continue Reading
Ascletis' Preclinical Successes: Future of Obesity Treatment

Updated Category News Views 14

Pharma Giants Eyeing a New Potential Well, it seems the world of pharma is buzzing with Ascletis’ latest developments in the obesity treatment arena. They’ve just showcased some intriguing preclinical data at ObesityWeek® 2026. The standout? A cocktail of advancements that might just put a dent in the obesity epidemic if further studies pan out. ASC30_48: A Daily...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 412

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Fapon's MEDICA 2026 Bid: Game-Changer or Same Old?

Updated Category News Views 89

Fapon's Ambitious Pitch at MEDICA: A Real Deal? MEDICA 2026 sees Fapon stepping up, laden with flashy promises and hardened expertise. Set up in Düsseldorf, these folks are pushing their Local Manufacturing Solutions harder than a door-to-door vacuum seller. The main pitch? Bolstering local IVD production with their comprehensive tech transfer services. How many outfits...

Continue Reading
Local Voices to Shape Mekong's Story in New Alliance

Updated Category News Views 284

Unpacking the New Storytelling Strategy Right off the bat, let's make it clear—this isn't just another run-of-the-mill environmental project announcement. When the National Geographic Society teams up with ThaiBev to empower Southeast Asian storytellers, they're not just waving around the usual conservation banner. Instead, they're betting on local voices to lead the...

Continue Reading
Akeso's Gumokimab Wins NMPA Approval for AS Treatment

Updated Category News Views 115

Gumokimab Approved: A New Dawn in AS Treatment Yeah, the biotech world shifts gears today as Akeso's gumokimab received the green light from China's National Medical Products Administration (NMPA). This approval for treating ankylosing spondylitis, or AS, isn't just another checkbox for Akeso; it's a game-changer in tackling this chronic inflammatory disease. Why should...

Continue Reading

Top 5 Most Recently Viewed Articles

O-I Glass Announces Participation in Citi’s 2025 Conference

Updated Category News Views 208

O-I Glass Participation in the 2025 Basic Materials Conference PERRYSBURG, Ohio — O-I Glass, Inc., known for its commitment to creating exceptional glass products, is set to participate in the upcoming Citi’s 2025 Basic Materials Conference. This significant event will take place on a Wednesday in December, and features notable presentations from O-I's leadership....

Continue Reading
Osmium Partners Proposes Strategic Plan for Articore Growth

Updated Category News Views 104

Osmium Partners Proposes a Four-Step Plan for Articore Osmium Partners has recently made headlines with their proposal for Articore, aiming to elevate shareholder value through a methodical four-step approach. This initiative is driven by Osmium's belief that Articore's current management strategy lacks direction and has resulted in missed opportunities for growth and...

Continue Reading
Amplify Energy Set to Shine at EnerCom Denver Conference 2025

Updated Category News Views 135

Amplify Energy’s Participation in EnerCom Denver Conference Amplify Energy Corp. is gearing up to participate in the renowned annual EnerCom Denver Conference in 2025. This event, known for bringing together leading experts and investors in the energy sector, offers Amplify a prime platform to showcase its strategic initiatives and growth potential. Focus on Investor...

Continue Reading
Safe Life Expands CPR Training and AED Services through Acquisition

Updated Category News Views 197

Safe Life Strengthens National Coverage for Life-Saving Training Safe Life has made a significant move by acquiring HeartCert, a company known for its specialization in automated external defibrillators (AEDs) and CPR training. This acquisition allows Safe Life to broaden its reach into the Midwest, enhancing its commitment to providing life-saving training and equipment...

Continue Reading
Express Scripts Challenges FTC's Drug Pricing Conclusions

Updated Category News Views 106

Express Scripts Files Lawsuit Against the FTC Express Scripts, a major player in the pharmacy benefit manager sector, has recently taken legal action against the U.S. Federal Trade Commission (FTC). This lawsuit stems from a report that criticizes the role of pharmacy benefit managers in the pricing of medications. Express Scripts contends that the report's conclusions...

Continue Reading